General
Preferred name
MEGESTROL ACETATE
Synonyms
SC10363 ()
BDH1298 ()
BDH1298, SC10363 ()
Megestrol acetateMegestrolMegaceProgesterone, 6-dehydro-17-hydroxy-6-methyl-, acetate17-Acetoxy-6-methylpregna-4,6-diene-3,20-dioneMegestryl acetate6-Methyl-6-dehydro-17.alpha.-acetylprogesterone6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone ()
Megestryl Acetate ()
Megestrol 17.alpha.-acetate ()
5071 ()
megestrol ()
Megace ()
Chronopil ()
NSC-71423 ()
BDH 1298 ()
SC 10363 ()
BDH-1298 ()
Megace Es ()
Megesterol acetate ()
SC-10363 ()
P&D ID
PD003106
CAS
595-33-5
51154-23-5
Tags
available
drug
Approved by
FDA
First approval
1971
Drug Status
vet_approved
approved
withdrawn
investigational
Max Phase
4.0
Drug indication
Chronic obstructive pulmonary disease
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE The major route of drug elimination in humans is urine. ; Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces.
PRICE 29
DESCRIPTION Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway[1][2][3][4][5].
DESCRIPTION Megestrol acetate (BDH1298) is a progestogen with actions and uses similar to those of the progestogens in general. Megestrol acetate also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia. (TargetMol Bioactive Compound Library)
DESCRIPTION Potent aryl hydrocarbon receptor (AhR) agonist; orally bioavailable (Tocris Bioactive Compound Library)
Compound Sets
21
AdooQ Bioactive Compound Library
A10563
Cayman Chemical Bioactives
21749
ChEMBL Approved Drugs
CHEMBL1201139
ChEMBL Drugs
CHEMBL1201139
Drug Repurposing Hub
DrugBank
DB00351
DrugBank Approved Drugs
DB00351
DrugCentral
1667
DrugCentral Approved Drugs
1667
EU-OPENSCREEN Bioactive Compound Library
EOS100374
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1201139
MedChem Express Bioactive Compound Library
HY-13676
NIH Approved Oncology Drugs
114395
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Megestrol-Acetate
TargetMol Bioactive Compound Library
T1284
Tocris Bioactive Compound Library
6285
Withdrawn 2.0
w201
External IDs
45
Properties
(calculated by RDKit )
Molecular Weight
384.23
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
4
Aromatic Ring Count
0
cLogP
4.58
TPSA
60.44
Fraction CSP3
0.71
Chiral centers
6.0
Largest ring
6.0
QED
0.65
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
Endocrinology/Hormones
Microbiology/virology
Proteases/Proteasome
Anti-infection
Vitamin D Related/Nuclear Receptor
Primary Target
Progesterone Receptors
MOA
Agonist
Progesterone receptor agonist
Disease Area
neurology/psychiatry, endocrinology
Indication
anorexia, cachexia
Target
NR3C1, PGR
HIV
Progesterone Receptor
Androgen Receptor,Estrogen/progestogen Receptor
ER
Glucocorticoid Receptor
ATC
G03DB02
G03AC05
L02AB01
Toxicity type
carcinogenicity
Source data